Loader

Pathways

PathWhiz ID Pathway Meta Data

PW122311

Pw122311 View Pathway
metabolic

Beta-oxidation

Homo sapiens

PW000187

Pw000187 View Pathway
disease

beta-Ureidopropionase Deficiency

Homo sapiens
Beta-ureidopropionase deficiency (Beta Alanine-Synthase Deficiency, UPB1, BUP1) is an autosomal recessive disease caused by mutations in the UPB1 gene which codes for beta-ureidopropionase. A deficiency in this enzyme results in accumulation of N-carbamyl-beta-amino acids. Symptoms include hypotonia, dystonic movements, scoliosis, microcephaly, and severe developmental delay.

PW121709

Pw121709 View Pathway
disease

beta-Ureidopropionase Deficiency

Mus musculus
Beta-ureidopropionase deficiency (Beta Alanine-Synthase Deficiency, UPB1, BUP1) is an autosomal recessive disease caused by mutations in the UPB1 gene which codes for beta-ureidopropionase. A deficiency in this enzyme results in accumulation of N-carbamyl-beta-amino acids. Symptoms include hypotonia, dystonic movements, scoliosis, microcephaly, and severe developmental delay.

PW127283

Pw127283 View Pathway
disease

beta-Ureidopropionase Deficiency

Homo sapiens
Beta-ureidopropionase deficiency (Beta Alanine-Synthase Deficiency, UPB1, BUP1) is an autosomal recessive disease caused by mutations in the UPB1 gene which codes for beta-ureidopropionase. A deficiency in this enzyme results in accumulation of N-carbamyl-beta-amino acids. Symptoms include hypotonia, dystonic movements, scoliosis, microcephaly, and severe developmental delay.

PW121934

Pw121934 View Pathway
disease

beta-Ureidopropionase Deficiency

Rattus norvegicus
Beta-ureidopropionase deficiency (Beta Alanine-Synthase Deficiency, UPB1, BUP1) is an autosomal recessive disease caused by mutations in the UPB1 gene which codes for beta-ureidopropionase. A deficiency in this enzyme results in accumulation of N-carbamyl-beta-amino acids. Symptoms include hypotonia, dystonic movements, scoliosis, microcephaly, and severe developmental delay.

PW061694

Pw061694 View Pathway
drug action

Betahistine H1-Antihistamine Action

Homo sapiens
Betahistine is a first-generation H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW176323

Pw176323 View Pathway
metabolic

Betahistine Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW126232

Pw126232 View Pathway
metabolic

Betaine Drug Metabolism

Homo sapiens
Betaine is obtained from foods such as wheat, shellfish, spinach, and beets. In the intestine, betaine is metabolized to trimethylamine (TMA) by the gut microbiota (Peptoclostridium acidaminophilum). The toxicity of betaine is due to the formation of TMA and its metabolism to Trimethylamine N-oxide (TMAO) in the liver. TMA is created from betaine via the enzyme betaine reductase in the intestinal microbe, then TMA then enters the bloodstream and is transported to the liver where dimethylaniline monooxygenase [N-oxide-forming] 3 converts TMA to TMAO. TMAO has negative effects on organs such as the heart, kidney and vascular system by contributing to cardiovascular disease, atherosclerosis, endothelial dysfunction and kidney disease.

PW145771

Pw145771 View Pathway
drug action

Betaine Drug Metabolism Action Pathway

Homo sapiens

PW088201

Pw088201 View Pathway
metabolic

Betaine Metabolism

Bos taurus
Betaine (or trimethylglycine) is similar to choline (trimethylaminoethanol) but differs in choline's terminal carboxylic acid group trimethylglycine is reduced to a hydroxyl group. Betaine is obtained from diet as betaine or compounds containing choline in foods such as whole grains, beets and spinach. Betaine can also be synthesized from choline in the liver and kidney. First, choline is oxidized to betaine aldehyde by mitochondrial choline oxidase (choline dehydrogenase). Then, betaine aldehyde dehydrogenase oxidizes betaine aldehyde to betaine in the mitochondria or cytoplasm. In the liver, betaine functions as a methyl donor similar to choline, folic acid, S-adenosyl methionine and vitamin B12. Methyl donors are important for liver function, cellular replication and detoxification reactions. Betaine is also involved in the production of carnitine to protect from kidney damage and functions as an osmoprotectant in the inner medulla.